A. Islam u. a.: High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. In: Oncogene 19, 2000, S. 617–623, PMID 10698506, doi:10.1038/sj.onc.1203358.
K. D. Lewis, W. Samlowski u. a.: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. In: Investigational new drugs. Band 29, Nummer 1, Februar 2011, S. 161–166, doi:10.1007/s10637-009-9333-6, PMID 19830389.
T. Nakahara u. a.: YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts. In: Cancer Research 67, 2007, S. 8014–8021; doi:10.1158/0008-5472.CAN-07-1343, PMID 17804712.
T. Hayashibara u. a.: Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: A prospective agent for adult T cell leukemia chemotherapy. In: Nutrition and Cancer, 44, 2002, S. 192–201, PMID 12734068, doi:10.1207/S15327914NC4402_12.
G. Ambrosini u. a.: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. In: Nature Medicine. Bd. 8, 1997, S. 917–921, PMID 9256286.
N. E. Crook u. a.: An apoptosis-inhibiting baculovirus gene with a zinc fingerlike motif. In: J. Virol. 67, 1993, S. 2168–2174, PMID 8445726, PMC 240327 (freier Volltext).
R. J. Clem u. a.: Control of programmed cell death by the baculovirus genes p35 and iap. In: Mol. Cell Biol. 14, 1994, S. 5212–5222, PMID 8035800, PMC 359040 (freier Volltext).
L. Chantalat u. a.: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. In: Mol Cell 6, 2000, S. 183–189, PMID 10949039.
D. Grossman u. a.: Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. In: J. Clin. Invest. 108, 2001 S. 991–999, PMID 11581300, PMC 200956 (freier Volltext).
E. M. Conway u. a.: Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. In: Gastroenterology. 123, 2002, S. 619–631, PMID 12145814.
H. Marusawa u. a.: HBXIP functions as a cofactor of survivin in apoptosis suppression. In: Embo J. 22, 2003, S. 2729–2740, PMID 12773388, PMC 156760 (freier Volltext).
S. F. Shariat u. a.: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. In: J Urol 171, 2004, S. 626–630, PMID 14713774.
D. B. Longley, P. G. Johnston: Molecular mechanisms of drug resistance. In: J Pathol 205, 2005, S. 275–292, PMID 15641020.
A. Islam u. a.: High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. In: Oncogene 19, 2000, S. 617–623, PMID 10698506, doi:10.1038/sj.onc.1203358.
B. M. Ryan u. a.: Survivin: a new target for anti-cancer therapy. In: Cancer Treat Rev 35, 2009, S. 553–562, PMID 19559538 (Review).
G. Giaccone u. a.: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. In: J Clin Oncol 27, 2009, S. 4481–4486, PMID 19687333.
K. D. Lewis, W. Samlowski u. a.: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. In: Investigational new drugs. Band 29, Nummer 1, Februar 2011, S. 161–166, doi:10.1007/s10637-009-9333-6, PMID 19830389.
T. Nakahara u. a.: YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts. In: Cancer Research 67, 2007, S. 8014–8021; doi:10.1158/0008-5472.CAN-07-1343, PMID 17804712.
M. H. Andersen u. a.: Cancer treatment: the combination of vaccination with other therapies. In: Cancer Immunol Immunother 57, 2008, S. 1735–1743, PMID 18286284 (Review), PMC 2522294 (freier Volltext).
T. Hayashibara u. a.: Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: A prospective agent for adult T cell leukemia chemotherapy. In: Nutrition and Cancer, 44, 2002, S. 192–201, PMID 12734068, doi:10.1207/S15327914NC4402_12.